Ionis announces eplontersen receives orphan drug designation from U.S. FDA

CARLSBAD, Calif. , Jan. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the